Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chemotherapy-induced Nausea and Vomiting Clear all

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant, Dexamethasone, Placebo, Ondansetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 23
States / cities: Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more

Conditions: Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Real Acupressure Band, Placebo Acupressure Band; Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 18 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Oral GW679769, IV Cyclophosphamide 500-700mg/m2; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: OLA group: Olanzapine, DEX group: Dexamethasone; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ondansetron, moxifloxacin, saline; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Interventions: Olanzapine, Placebo Oral Tablet; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 30 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more

Conditions: Chemotherapy Induced Nausea and Vomiting
Interventions: Akynzeo; Drug
Lead sponsor: Simon Williamson Clinic; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Mount Olive, Alabama

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant - Oral, Rolapitant - IV; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: fosaprepitant, aprepitant, Oral Placebo, IV placebo; Drug · Other
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Chemotherapy Induced Nausea and Vomiting
Interventions: granisetron transdermal system, Granisetron IV; Drug
Lead sponsor: Kyowa Kirin Pharmaceutical Development Ltd; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 8 more

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Overland Park, Kansas • Buffalo, New York • Columbus, Ohio

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg; Drug
Lead sponsor: Xiamen LP Pharmaceutical Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more

Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: casopitant, dolasetron, granisetron, rosiglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions: GW679769, Dexamethasone, Ondansetron Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 47
States / cities: Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more

Conditions: Gynecologic Cancer
Interventions: Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: APF530, dexamethasone, Palonosetron Hydrochloride, placebo; Drug · Other
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 52
States / cities: Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more

Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dolasetron mesylate, granisetron hydrochloride, ondansetron, tropisetron, quality-of-life assessment; Drug · Procedure
Lead sponsor: Gary Morrow; Other
Eligibility: 18 Years to 120 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 2
States / cities: Hackensack, New Jersey • Rochester, New York

Conditions: Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions: Essential oils, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Interventions: Otoband, Placebo device; Device
Lead sponsor: Otolith Labs; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 11
States / cities: Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more

Conditions: Malignant Neoplasm
Interventions: Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 565
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant, Granisetron, Dexamethasone, Placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Search by objective public record fields.

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

Cyclophosphamide Drug Interaction Study In Cancer Patients

Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

Use of Aromatherapy to Reduce Symptom Burden

Prevention of Unmitigated Chemotherapy-induced Emesis

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy